Completed PHASE2 INTERVENTIONAL 2-arm NCT00819338

The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease

The Effect of n-3 Polyunsaturated Fatty Acid Supplementation in Patients With Non-alcoholic Fatty Liver Disease

Sponsor: University of Nottingham

Conditions Non-alcoholic Fatty Liver Disease

Interventions Efamax

Updated 5 times since 2017 Last updated: Jul 3, 2012 Started: Jan 31, 2009 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00819338, this PHASE2 trial focuses on Non-alcoholic Fatty Liver Disease and remains completed. Sponsored by University of Nottingham, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Nottingham

Data source: University of Nottingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nottingham, United Kingdom